Status:
COMPLETED
ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)
Lead Sponsor:
DxTerity Diagnostics
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Brief Summary
To explore the potential for use of DxTerity's AIP IFN-1 test as personalized guided care and monitoring module in patients with Systemic lupus erythematosus(SLE) using consented patient health inform...
Detailed Description
Explore and demonstrate concordance between self-collected samples and traditional phlebotomist venous draw for DxTerity AIP module and biomarkers like C3, C4, anti dsDNA and CRP in SLE participants w...
Eligibility Criteria
Inclusion
- (PHASE I)
- Individuals aged 18 years or older.
- Must reside in United States
- Have a clinical diagnosis of SLE
- Willingness to consent to provide electronic medical records (EMR)
- Provide written informed consent and comply with the study procedures.
- (PHASE II)
- Verified diagnosis (Medical records or /and Physician Questionnaire) for SLE
- Report one or more of the following (record all that apply):
- Worsening or changes in symptoms or flare
- Changes in treatment regimen
- On standard of care treatment
- On biologics
Exclusion
- 1\. Participants unable to complete study requirements
Key Trial Info
Start Date :
May 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 17 2023
Estimated Enrollment :
423 Patients enrolled
Trial Details
Trial ID
NCT05347992
Start Date
May 3 2022
End Date
August 17 2023
Last Update
January 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DxTerity Diagnostics, Inc.
Compton, California, United States, 90220